Senolytics: Dasatinib + Quercetin

Cellular senescence is the state in which cells permanently exit the cell cycle following DNA damage, oncogenic stress, or other insults. Senescent cells are not benign: they resist apoptosis and secrete a complex pro-inflammatory cocktail — the senescence-associated secretory phenotype (SASP) — that includes IL-6, IL-1α, TNF-α, MMPs, and growth factors. SASP damages surrounding tissue, recruits immune cells, drives chronic low-grade inflammation, and propagates senescence to neighboring cells. The accumulation of senescent cells in tissues is now considered a primary cause — not merely a correlate — of aging and age-related disease. Senolytics are compounds that selectively eliminate senescent cells by exploiting their survival vulnerabilities. The dasatinib + quercetin (D+Q) combination was developed at the Mayo Clinic as the first senolytic protocol and published to immediate scientific impact in 2015. The rationale: dasatinib (a tyrosine kinase inhibitor approved for leukemia) targets pro-survival BCR-ABL and Src pathways overexpressed in senescent cells; quercetin (a plant flavonoid) inhibits PI3K/Akt survival signaling. Together, they hit complementary anti-apoptotic networks uniquely upregulated in senescent cells, while leaving normal cells relatively unaffected. The critical human evidence: the first published human senolytic trial (PMID 31542391) tested D 100mg + Q 1000mg × 3 consecutive days in patients with idiopathic pulmonary fibrosis. Results were striking — a 35% reduction in p16INK4a-positive senescent cells in adipose tissue biopsies, with concurrent reductions in circulating IL-1α and IL-6. Physical function improved significantly. Preclinical evidence now spans 40+ age-related conditions across cardiovascular disease, neurodegeneration, metabolic dysfunction, and musculoskeletal decline (PMC7790861). The standard senolytic protocol uses intermittent pulse dosing — 2 to 3 consecutive days per month — rather than chronic daily dosing. This aligns with the biological rationale: senescent cells accumulate over weeks to months, and clearance events followed by recovery periods may be more effective than continuous low-level exposure. Dasatinib requires prescription access and carries significant interaction risks; quercetin is OTC. The combination should not be attempted without physician oversight and appropriate baseline assessment.